Results from study indicate strong healing rate of chronic venous ulcers when VenaSeal™ is used in patients with advanced superficial venous disease
Medtronic, the global leader in health care technology, today announced the primary and...
Results from study indicate strong healing rate of chronic venous ulcers when VenaSeal™ is used in patients with advanced superficial venous disease
Medtronic, the global leader in health care technology, today announced the primary and...
EFEMORAL I is a first-in-human clinical trial evaluating the performance of the Efemoral Vascular Scaffold System (EVSS) for the treatment of patients suffering symptomatic peripheral arterial occlusive disease from atherosclerosis of the...
EFEMORAL I is a first-in-human clinical trial evaluating the performance of the Efemoral Vascular Scaffold System (EVSS) for the treatment of patients suffering symptomatic peripheral arterial occlusive disease from atherosclerosis of the...
MALVERN Pa., (April 22, 2025) — Insights and innovations in limb preservation are the focus of HMP Global’s 15th annual Amputation Prevention Symposium (AMP). With the theme of “Where the Field Moves Ahead,” AMP this year introduces Lead...
MALVERN Pa., (April 22, 2025) — Insights and innovations in limb preservation are the focus of HMP Global’s 15th annual Amputation Prevention Symposium (AMP). With the theme of “Where the Field Moves Ahead,” AMP this year introduces Lead...
2025 meeting led by Dr. Richard Neville and Dr. Bret Wiechmann; new Course Directors include Dr. Kumar Madassery, Dr. John Phillips, and Dr. Ahmed Kayssi
MALVERN Pa., (April 22, 2025) — Insights and innovations in limb preservation are the...
2025 meeting led by Dr. Richard Neville and Dr. Bret Wiechmann; new Course Directors include Dr. Kumar Madassery, Dr. John Phillips, and Dr. Ahmed Kayssi
MALVERN Pa., (April 22, 2025) — Insights and innovations in limb preservation are the...
The first patient in its ELITE-BTK pivotal trial was treated by Dr. Brian DeRubertis, FACS, Chief of the Division of Vascular & Endovascular Surgery at NewYork-Presbyterian and Weill Cornell Medicine in New York City.
The first patient in its ELITE-BTK pivotal trial was treated by Dr. Brian DeRubertis, FACS, Chief of the Division of Vascular & Endovascular Surgery at NewYork-Presbyterian and Weill Cornell Medicine in New York City.
This prospective, randomized (2:1 treatment to control) dual-center study will enroll up to 60 subjects. The study will utilize intravascular optical coherence tomography (OCT) imaging to demonstrate the mechanism of action (MOA) of the...
This prospective, randomized (2:1 treatment to control) dual-center study will enroll up to 60 subjects. The study will utilize intravascular optical coherence tomography (OCT) imaging to demonstrate the mechanism of action (MOA) of the...
The data demonstrated high rates of reperfusion and first-pass success with a strong safety profile, supporting the ANA device as an adjunct to stent retriever thrombectomy in the treatment of acute ischemic stroke.
The data demonstrated high rates of reperfusion and first-pass success with a strong safety profile, supporting the ANA device as an adjunct to stent retriever thrombectomy in the treatment of acute ischemic stroke.
Society for Vascular Surgery urges primary care providers to work with vascular surgeons to enhance patient outcomes and quality of life
ROSEMONT, Ill., April 15, 2025 /PRNewswire/ -- According to a new national survey released by the...
Society for Vascular Surgery urges primary care providers to work with vascular surgeons to enhance patient outcomes and quality of life
ROSEMONT, Ill., April 15, 2025 /PRNewswire/ -- According to a new national survey released by the...
Penumbra, Inc, announced seven significant computer assisted vacuum thrombectomy (CAVT™) data presentations during the 2025 Society of Interventional Radiology (SIR) Annual Scientific Meeting. The data showed that CAVT as a frontline therapy...
Penumbra, Inc, announced seven significant computer assisted vacuum thrombectomy (CAVT™) data presentations during the 2025 Society of Interventional Radiology (SIR) Annual Scientific Meeting. The data showed that CAVT as a frontline therapy...
FLAGSTAFF, Ariz. (March 24, 2025) — W. L. Gore & Associates (Gore) today announced the expansion of the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System product line, following FDA approval of four new large-diameter...
FLAGSTAFF, Ariz. (March 24, 2025) — W. L. Gore & Associates (Gore) today announced the expansion of the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System product line, following FDA approval of four new large-diameter...
